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ABSTRACT 
 
Mycobacterium Tuberculosis is the leading cause of morbidity and mortality due to infectious 
diseases worldwide. South Africa has ~20% of the world’s HIV associated Tuberculosis and has the 
second largest reported numbers of multidrug resistant (MDR) Tuberculosis in the world. 
Given the complexity of the mycobacterium and its ability to evade the immune system, there is a 
need for dissecting the immunological response to Tuberculosis including innate like lymphocytes 
such as gamma-delta T cells. Gamma-delta T cells are of particular relevance as they react to 
phospho-proteins of mycobacteria. Gamma-delta T cells can be divided into two subsets. Gamma-
delta T cells using the Vdelta2 (VD2) segment as the variable segment in their T cell receptor and 
gamma-delta T cells using an alternative variable segment (non VD2 T cells). 
We aimed to enumerate both subsets of gamma-delta T cells in the immunological response to 
Tuberculosis. We collected samples from three patient populations at the Charlotte Maxeke 
Johannesburg Academic Hospital for comparison: HIV positive patients with no evidence of 
Tuberculosis disease, HIV positive patients with active pulmonary Tuberculosis and a healthy 
control group. We used a nine colour flow cytometric panel to enumerate the frequency of gamma-
delta T cells in these participant groups. 
We found that the VD2 T cell subset was reduced in the HIV positive group and the dual HIV 
positive TB positive group compared with healthy controls, which mirrored the loss of CD4 T cells 
in these patients. Conversely, the non VD2 subset of gamma-delta T cells showed a statistically 
significant increased frequency in HIV positive patients and dual HIV positive TB positive patients 
compared to healthy controls. The frequency of gamma-delta T cells, expressed as a percentage of 
total T cells, was significantly increased in HIV positive patients and not non- significantly 
increased in the HIV positive TB positive groups compared to healthy controls. 
This skewing of the gamma-delta T cell repertoire in HIV positive patients and HIV positive patients 
with active Tuberculosis may have specific immune implications. The mechanism of the loss of 
VD2 T cells in HIV and HIV associated Tuberculosis has not been elucidated. The loss of VD2 
gamma-delta T cells in HIV and HIV associated Tuberculosis may underlie susceptibility to 
Tuberculosis disease. 
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1. INTRODUCTION 
 
1.1. Tuberculosis in the third world 
Tuberculosis (TB) remains a global health problem. According to the Global Tuberculosis Report, 
2013, an estimated 8.6 million people developed Tuberculosis and 1.3 million of these patients 
died from the disease in 2012. An estimated 1.1 million (13%) of the 8.6 million people who 
developed TB in 2012 were HIV positive. About 75% of these cases were in the African Region. 
In 2012, an estimated 450 000 people developed Multi Drug Resistant Tuberculosis (MDR-TB) 
and there were an estimated 170 000 deaths from MDR-TB. The majority of cases worldwide in 
2012 were in the South-East Asia (29%), Africa (19%) and Western Pacific (19%) regions. The 
TB incidence rate in South Africa is currently around 1000 or more cases per 100 000 people (1, 
2). 
Most Tuberculosis patients are in their 20s to 40s resulting in a devastating socio-economic loss. 
Population expansion, poor case detection and cure rates in developing countries, ongoing 
transmission, overcrowding in hospitals and prisons, migration due to wars and famine, drug abuse 
and social decay has all impacted on the TB disease burden (3). 
In addition, co-infection with HIV also worsens the disease burden with ~50% of HIV positive 
patients at risk of TB. The WHO estimates that 80% of HIV infected TB patients reside in Africa 
(4). 
The emergence of multi-drug resistant (MDR) TB (strains of M.TB resistant to two first line drugs) 
and extensive drug resistant (XDR) TB (strains of M.TB resistant to fluoroquinolone, kanamycin 
and amikacin) has also been reported in 55 countries around the world. MDR-TB is difficult and 
expensive to treat while XDR-TB is virtually untreatable in most developing countries (5, 6). 
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1.2. History of Tuberculosis disease 
Mycobacterium Tuberculosis is an ancient organism that has inhabited the earth for centuries. 
Egyptian mummies which existed several thousand years BC have shown evidence of spinal 
Tuberculosis. Tuberculosis references can be found in the ancient Babylonian and Chinese 
scriptures. In more recent times, molecular genetic studies have revealed that Tuberculosis is ~3 
million years old (3). 
1.3. Natural history of Mycobacterium Tuberculosis 
Tuberculosis is usually spread by individuals with active pulmonary TB. These Tuberculosis 
patients usually reside in close proximity to other family and community members, thus facilitating 
the spread of the disease (3). 
Mycobacterium Tuberculosis is usually acquired by inhaling aerosolized mycobacteria from the 
environment. These bacterial droplets are ~1-5µm and remain suspended in the air for several 
hours. The risk of an individual contracting the infection depends on the infectiousness and 
proximity of the contact, the bacillary load and the immune status of the host (7). 
1.3.1. Primary infection 
The epithelium of the lung is the primary site of infection. The inhaled droplet nuclei are able to 
penetrate the terminal alveoli where they are engulfed by phagocytes. Phagocytes are cells of the 
innate immune system and include macrophages and dendritic cells. Once internalized by these 
phagocytes, the mycobacterium is able to replicate intra-cellularly. Some of these infected cells 
may be able to cross the alveolar barrier in the lung and cause systemic dissemination. 
Dissemination occurs to the lymph nodes and to various other extra pulmonary sites such as the 
liver, kidney and bone marrow. The initial focus of infection in the lung epithelium and lymph 
nodes is called the ghon complex and represents primary TB infection (8, 9). 
1.3.2. Latent Tuberculosis infection (LTBI) 
In most individuals who are not immune compromised, an effective immune response develops 
soon after infection which halts further replication of the mycobacterium (3). Granulomas 
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represent a part of this immune response. Granulomas are confined areas of necrotic tissue that 
wall off the infection and prevent dissemination. The tubercle bacilli are also destroyed within 
these caseating granulomas if an effective immune response in the host is established (7, 10, 11). 
Despite the development of an adaptive immune response to the mycobacterium, the pathogen is 
often able to survive in this protected niche in the lung and avoid complete elimination for many 
years, resulting in latent TB infection (10, 11). 
1.3.3. Reactivation of latent Tuberculosis 
Latent Tuberculosis is defined as infection with M.TB in foci within granulomas which remain in 
a non-replicating state but retains the ability to emerge and cause active TB when immune 
deregulation occurs (12). 
When the host immune response is compromised, as occurs with old age, diabetes mellitus, 
malnutrition, renal failure and immunosuppressive treatments, reactivation of latent Tuberculosis 
can occur (7, 13-15). HIV is the leading cause of reactivation due to depletion of CD4+ T cells (4, 
15). With reactivation, the dormant bacilli, found in the macrophages within the granulomas 
migrate towards a new area of the lung epithelium to establish a new focus of infection (16-19). 
Reactivation often occurs in the upper lobes of the lung where severe necrosis and cavitation 
occurs (17, 20). 
1.3.4. Symptoms of disease from Tuberculosis 
Patients may develop influenza like symptoms that resolve within a few days. Progressive primary 
infection or reactivation of pulmonary Tuberculosis manifests with numerous classical symptoms 
including a cough which is productive of sputum or blood, drenching night sweats, fatigue, fever 
and loss of weight. Patients may also experience difficulties in breathing, chest pains and 
wheezing. If systemic dissemination has occurred, patients will present with organ symptoms 
depending on the site of the Tuberculosis reactivation. 
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1.4. The immunology of Tuberculosis 
 
1.4.1. The innate immune response to Tuberculosis 
Mycobacterium Tuberculosis has a predilection for lung tissue and is able to penetrate the terminal 
alveoli where it is engulfed by phagocytic cells of the innate immune system to form a 
phagolysosome. Recognition of the bacillus occurs when pathogen recognition receptors (PRRs) 
on the phagocytes identify certain pathogen-associated molecular patterns (PAMP) of the 
mycobacterium (21).This process is followed by recognition of the mycobacterium by Toll-like 
receptors (TLR), nucleotide binding oligomerization domain-like receptors (NOD) and C-type 
lectins (CD201, DC-SIGN and Dectin-1) which are all receptors of the innate immune response 
(22, 23). Interaction of the mycobacterium with these receptors initiates an intra-cellular signaling 
cascade through nuclear factor–Κ B (NF-ΚB) resulting in a pro-inflammatory and antimicrobial 
response. The pro-inflammatory response to the mycobacterium allows the migration of 
monocytes, neutrophils and lymphocytes to the focal site of infection in the lung with the 
consequent formation of a phagolysosome (22, 23). 
Innate immunity is the first line of defense against infections present in all multicellular organisms. 
Components of the innate immune system in humans include epithelia, phagocytic cells, natural 
killer (NK) cells, cytokines, complement components and plasma proteins (24). 
Natural killer (NK) cells are lymphocytes capable of killing microbe infected cells and activating 
phagocytes by secreting interferon-gamma (IFN-gamma). NK cells do not express 
immunoglobulin or T cell receptors. They are regulated by cell surface stimulatory and inhibitory 
receptors which recognize major histocompatibility complex molecules. NK cells also express 
CD56 and the receptor CD16 that binds to IgG antibodies on cells. These receptor mediated signals 
stimulate the NK cells to release their cytotoxic granules which are able to kill opsonized targets 
in a process which is known as antibody dependent cytotoxic killing (ADCC) (24). During 
Tuberculosis infection, natural killer cells are able to kill microbial pathogens via this cytotoxic 
response (25). 
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1.4.2. The Adaptive Immune response to Tuberculosis 
Adaptive immunity also plays a crucial role in the host response to the mycobacterium. Dendritic 
cells engulf bacilli and migrate to regional lymph nodes to prime CD4+ T and CD8+ T cells. The 
activated T cells are stimulated by chemokine signaling and migrate back to the focus of infection 
in the lung to begin manufacturing of the granuloma (26). 
The granuloma is an enclosed area of inflammation which is able to contain the tubercle bacilli 
from the rest of the lung epithelium thus attempting to limit the spread of bacteria. Within the 
granuloma, numerous cells are actively involved in forming an effective host immune response to 
the mycobacterium (27). Macrophages carrying Tuberculosis antigens present peptide antigens to 
CD4+ T cells in an immunological synapse resulting in the production of tumor necrosis factor 
(TNF) and IFN-gamma (28). These cytokines activate macrophages which generate nitric oxide 
(NO). This NO along with other substances is toxic to the bacilli and is thought to eliminate it (29-
31). Cytotoxic T cells can directly kill the mycobacterium via the granulysin effect (29-31). This 
process represents a protective immune response which is manifested clinically by a positive 
tuberculin skin test and resistance to re-infection (7, 26). 
1.4.3. Tuberculosis evades the immune response 
Despite this protective immune response to Mycobacterium Tuberculosis, the pathogen has 
developed numerous strategies to modulate and evade the immune response and persist in the host. 
The mycobacterium is able to avoid destruction by lysosomes in the phagolysosome and is also 
able to block maturation of the phagolysosome (32). The mycobacterium is able to modulate 
calcium signaling cascades which inhibits phagosome maturation and leads to enhanced 
intracellular survival (33-36). Mycobacterium tuberculosis can also inhibit apoptosis of 
macrophages which escapes host defenses (37). 
1.4.4. VDJ recombination and diversity of T cells 
There are two classes of T cells which are involved in adaptive immunity. The majority of the T 
cells in the body have alpha-beta T cell receptors. Another subset of T cells have gamma-delta T 
cell receptors and comprise <5% of all circulating T cells in healthy adults.  
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The T cell receptor (TCR) recognizes antigen but is unable to transmit signals to the T cell. 
Therefore, associated with the TCR is a complex of proteins called the CD3 molecules (three 
protein structures) and the zeta chain that make up the TCR complex. The CD3 and the zeta chains 
transmit some of the signals that are initiated when the TCR recognizes antigen.  Signal 
transduction occurs through tyrosine phosphorylation (24). 
The diversity of these antigen receptors on lymphocytes is produced as a result of VDJ 
recombination. This process involves the use of different combinations of V, D and J segments of 
the TCR gene in different clones of lymphocytes which introduces variability in T cell receptors 
and results in a diverse repertoire of lymphocytes with different receptors which are capable of 
recognizing different antigens (24, 38). 
Most T cells recognize only protein antigens in the context of MHC and have a wide range of 
specificities of antigen due to the diversity of their TCR repertoire (39). Gamma-delta T cells have 
a limited diversity of their TCR repertoire. The first crystallographic structure of the human gamma 
delta TCR was described in 2001 as a result of their unique surface expression of novel molecules 
(38, 40, 41). Gamma- delta T cells are referred to as invariant T cells. Gamma-delta T cells 
comprise <5% of all circulating T cells in healthy adults (38, 42). Gamma-delta T cells are the 
predominant cell type found on mucosal surfaces including the epithelial layers of the gut, tongue, 
lung and female reproductive tract (38, 43).           
1.4.5. Invariant T cells in Tuberculosis 
Mycobacterium Tuberculosis is structurally composed of a cell wall which is surrounded by a thick 
waxy mixture of lipids and polysaccharides and a high content of mycolic acids (44-47). CD4+ and 
CD8+ T cells are largely responsible for immune responses to peptides. Cells which respond to 
lipid antigens are CD1-resticted T cells (natural killer T cells) and cells which respond to 
phospholipids are the gamma-delta T cells. CD1-restricted T cells and gamma-delta T cells are 
unique T cell types which are specifically adapted to recognize these lipid and phospho-antigens 
on mucosal and epithelial surfaces (44, 45). Recent evidence suggests that gamma-delta T cells 
are important in the host immunity to mycobacteria (48). Gamma-delta T cells have been shown 
to recognize non-peptide metabolites of isoprenolol biosynthesis and lipid extracts of mycobacteria 
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(38, 49). Gamma-delta T cells do not require uptake, processing or intracellular loading on the 
MHC molecule for antigen presentation and are dependent on cell to cell contact (38, 49). These 
gamma-delta T cells express pro-inflammatory cytokines such as IFN-gamma which are cytotoxic 
to the mycobacterium (47, 50). 
1.4.6. Sputum testing for Tuberculosis 
TB diagnosis currently includes a detailed medical history, clinical examination as well as 
radiological, microbiological, immunological, molecular and histological investigations. The 
tuberculin skin test is an in vivo test which becomes positive six to eight weeks after exposure to 
the bacilli. The skin test is based on a delayed type hypersensitivity response. A skin reaction of 
>20mm is due to active tuberculosis disease. This test, however, lacks sensitivity and specificity 
(7, 51).Culture based detection of the mycobacterium in sputa has remained the gold standard of 
diagnosis until recently. Sputum acid fast bacilli (AFB) by microscopy is  the most common 
method of screening (52). The culture growth of Mycobacterium Tuberculosis takes on average 
two or more weeks. In addition, only 44% of all new cases (15-20% of children) are actually 
identified by the presence of (AFB) on sputum smears. The sensitivity of sputum smear 
microscopy is as low as ~35% in settings with TB and HIV co-infection. This results in difficulty 
in initiating anti-Tuberculosis treatment where AFBs are not detected by sputum smear 
microscopy (52). Tuberculosis drugs have potential side effects which can be debilitating and thus 
empiric Tuberculosis treatment is not ideal. Tuberculosis is treated for a period of six to nine 
months. Tuberculosis symptoms resolve after a few weeks of treatment and for these reasons, 
compliance is a major problem facing the health sector. As a result of noncompliance and failure 
to complete the full six months of anti-tuberculosis treatment, multidrug resistant and extensive 
drug resistant strains of Mycobacteria Tuberculosis are emerging with increasing frequency (5). 
1.4.7. Newer methods of testing for Tuberculosis 
More sensitive and specific tests based on the cell-mediated immune response to Tuberculosis 
include the IFN-gamma release assays (IGRA) which are able to detect T cell responses after 
stimulation by two mycobacterial antigens, the early secreted antigen target-6 (ESAT-6) and the 
culture filtrate protein-10 (CFP-10) (53-58). IGRA includes the Quantiferon Gold assay and the 
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ELISPOT test both of which have been FDA approved (59-62). While these assays can 
differentiate individuals who have been previously exposed to Tuberculosis from those who have 
never been exposed, they cannot differentiate latent from active disease and therefore lack utility 
in areas of high background Tuberculosis like South Africa (57, 60-63). 
This scenario is currently evolving with the roll out of the Xpert MTB/RIF (Cepheid) in South 
Africa which is a molecular assay with an increased sensitivity, reduced turn-around time and easy 
detection of rifampicin resistance (64). The Xpert MTB/RIF testing has shown superior 
performance for the rapid diagnoses of Mycobacterium Tuberculosis compared to current assays 
in an HIV and TB endemic areas such as South Africa (64). 
Molecular testing, however, still requires the presence of a suitable sample and may have 
limitations in groups who struggle to produce sputum as well as in non-sputum samples such as 
cavitatory fluids (65). 
1.4.8. Need to understand the immunological response to TB 
 
Due to this inadequacy of diagnostic tools and weak laboratory–based diagnoses of active TB, 
many cases remain under-diagnosed, further contributing to the morbidity, mortality and the 
continued transmission of the disease especially in those patients co-infected with HIV. 
As a result there is a clear need for the development of cost-effective and simple new tools for the 
reliable detection of Tuberculosis in HIV-infected and uninfected patients. 
Due to the pressure for strengthening earlier diagnosis in the paucibacillary stage, including 
sputum-negative pulmonary Tuberculosis, extra pulmonary Tuberculosis, childhood and neonatal 
Tuberculosis and Tuberculosis with HIV co-infection, there is an urgent need  to understand the 
immune response to Tuberculosis in order to develop new systems based on the immunological 
response to Mycobacterium Tuberculosis (52). A deeper understanding of the immunology of 
Tuberculosis may also lead to improved therapeutics and adjunctive treatments as well as 
monitoring tools for treatment outcome (66, 67). 
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1.5. Gamma-delta T cells in Tuberculosis and HIV 
It has long been known that it is the immune control of the mycobacterium that determines active 
Tuberculosis. A person can be latently infected with Tuberculosis, yet appear completely healthy 
(68). When his CD4 count falls beyond a certain point, however, he manifests with disease. 
Numerous studies have recently shown that gamma-delta T cells have an important role in 
defending the host against a very wide range of infections. Gamma-delta T cells are unique in the 
immune system as they have been shown to combine conventional adaptive functions with rapid, 
innate like responses in the initiation of immune responses (69). Six mechanisms have been 
attributed to gamma-delta T cells and recently reviewed (70). 
These mechanisms are listed below:  
1. Gamma-delta T cells lyse as well as eliminate infected cells via the production of granzymes 
2. Gamma-delta T cells produce a diverse range of cytokines and chemokines which regulates 
other immune cells 
3. Gamma-delta T cells assist B cell function. The B cells are then able to produce IgE 
4. Gamma-delta T cells present antigens for alpha-beta T cell priming 
5. Gamma-delta T cells can trigger dendritic cell maturation 
6. Gamma-delta T cells can regulate stromal cell function via growth factor production 
Given this diverse function in the immunological system, it is not surprising that gamma-delta T 
cells have also been shown to have an important role in HIV and Tuberculosis in several studies. 
There are conflicting studies regarding the distribution of gamma delta T cells during Tuberculosis 
infection. Studies show that gamma-delta T cells are increased in the peripheral blood and lungs 
of Tuberculosis patients (71, 72). It has been shown that gamma-delta T cells express an activation 
phenotype even after 5 weeks of Tuberculosis treatment (40). Gamma-delta T cells have also been 
shown to be involved in the formation of the Tuberculosis granuloma in humans, playing a role in 
the innate immune response to Tuberculosis (73). IL-17 producing gamma-delta T cells were 
increased in the peripheral blood of TB patients compared to healthy controls (74). The frequency 
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of gamma delta T cells in patients with mild Tuberculosis was increased compared to patients with 
advanced and pulmonary or miliary Tuberculosis (75). 
In contrast, some studies have suggested that gamma-delta T cells are reduced in the peripheral 
blood of TB and HIV infected patients compared to healthy controls (48). It was hypothesized that 
the reduction in the gamma-delta T cells in the peripheral blood of patients with active 
Tuberculosis may be a result of sequestration of reactive gamma-delta T cells to the site of 
infection in the lung epithelia (40). Another study, however, showed that gamma delta T cell 
subsets from broncho-alveolar lavage samples of patients with active Tuberculosis were 
functionally impaired (76). 
Several animal models have supported the role of gamma-delta T cells as modulators of 
Tuberculosis infection.  
Macaque Vgamma2Vdelta2 T cells have the capability to recognize mycobacterium phospho-
antigen (E)-4-hydroxy-3-methyl-but-2-enylpyrophosphate (HMBPP) (77). In a macaque model of 
infection with Mycobacterium Bovis Bacillus Calmette-Guerin (BCG), the gamma-delta T cells 
demonstrated clonal expansion during primary exposure. The expansion of gamma-delta T cells 
in the pulmonary compartment of these monkeys was associated with a decline of bacterial burden, 
resolution of active infection and immunity against fatal Tuberculosis. These findings 
demonstrated the importance of gamma-delta T cells in the innate immune response to 
Mycobacterium Tuberculosis in macaque monkeys (78). Recent studies have also shown that HIV 
infected macaque monkeys with high viral loads inhibit gamma-delta T cell responses in the blood 
and lungs. Tenofavir and indinavir anti-retroviral treatment of these monkeys were able to restore 
the capacity of  gamma-delta T cells to proliferate and undergo pulmonary migration in active 
Tuberculosis  re-infection, suggesting  the vital and protective role of gamma-delta T cells in dual 
HIV+ TB+ infection (79). 
 Recently, it was found that Vdelta2gamma-delta T cells were the essential populations producing 
IFN-gamma in response to BCG immunization in infants and children suggesting that these 
unconventional T cells are significant in the mycobacterial immune response (80). 
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1.6. Subsets of gamma-delta T cells 
Gamma-delta T cells are comprised of two subsets: Gamma-delta T cells which use the Vdelta2 
segment (VD2) as their variable segment and those that do not(41). These subsets belong to the 
same class of T cell types but have slightly different antigen specificities (24).Studies have found 
that these gamma-delta T cell subsets behave differently in HIV patients with opportunistic 
infections (81). 
1.7. Detection of gamma-delta T cells 
All lymphocytes arise from stem cells in the bone marrow. B lymphocytes undergo VDJ 
recombination in the bone marrow and T lymphocytes undergo VDJ recombination in the thymus. 
All lymphocytes are morphologically similar in appearance but differ with regard to function, 
lineage and phenotype (82). Different subtypes of B and T lymphocytes can be distinguished by 
surface proteins on the cell membrane. The standard nomenclature for these proteins is the CD or 
cluster of differentiation (24). 
Multicolour flow cytometry is a means of representing a very large amount of data involving cell 
surface receptors and cellular activation from a single sample. Flow cytometry can enable 
characterization of complex populations and immunological mechanisms within the human body 
(83-87). 
Given the importance of gamma-delta T cells in the immune system and their role in innate and 
adaptive immune responses, we aimed to assess the frequency of gamma-delta T cells in HIV and 
Tuberculosis infected patients in the South African setting where these infections are most 
prevalent. In order to delineate all the  cell subsets for specific assessment of gamma-delta T cell 
functions in HIV and TB populations, a series of T and B cell markers were chosen for our nine 
colour (multiparameter) panel. Included in our panel but not analyzed as part of this dissertation 
are markers of NK T cells. The chosen markers are indicated in table 1. 
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Table 1: Panel of CD markers selected 
 
CD number Main cellular expression Function 
CD19 Most B cells B cell activation; forms a co receptor complex with 
CD21 and CD81 which delivers signals that 
synergize with signals from B cell antigen receptor 
complex (24) 
CD3 T cells A lineage specific marker for T cells; for  cell 
surface expression of and signal transduction by the 
T cell antigen receptor (24) 
CD4 T helper cells(also found on 
monocytes and macrophages) 
Signaling and adhesion co-receptor in class 11 
MHC-restricted antigen-induced T cell activation 
(24) 
CD8 Alpha Cytotoxic T lymphocytes Signaling and adhesion co-receptor in class 1 MHC-
restricted antigen-induced T cell activation (binds to 
class 1 MHC molecules  (24) 
Gamma delta TCR Mucosal associated invariant  T cells; 
T cells with gamma delta TCR 
Recognize lipid  and non-protein antigens on 
epithelial surfaces (24) 
VD2 TCR A subset of gamma-delta T cells 
using the Vdelta2 variable segment 
in their TCR 
Recognize lipid and non-protein antigens on 
epithelial surfaces (24) 
CD16 NK cells Fc receptor (24) 
CD56 NK cells Responsible for adhesion (24) 
CD6B11 NK T cells Express the alpha beta TCR but recognize 
glycolipid and other non-peptide antigens displayed 
by non-polymorphic MHC-like molecules, e.g. 
CD1d (24) 
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Table 2: Our lineage description was as follows 
 
CELL MARKER: DESCRIPTION: 
CD3+  T cell  
CD3+  CD4+ CD4 T helper cell 
CD3+  CD8 ALPHA + CD8 cytotoxic T cell 
CD3+  GAMMA DELTA + Gamma-delta T cell 
CD3+ VD2 TCR+ VD2 TCR subset of gamma-delta T cell 
CD3+ GAMMA DELTA+ CD8+ Gamma-delta T cell expressing CD8+ 
CD3+ GAMMA DELTA+ VD2 TCR- Gamma-delta T cell that is not in the VD2 TCR subset 
(likely VD1 TCR subset) 
 
1.8. Overall aims of the study 
 
The primary aim of this study was to enumerate the frequency of gamma-delta T cells by flow 
cytometry in HIV+ patients and HIV+ TB+ infected patients in comparison with healthy controls 
in a South African setting. 
The secondary aim of the study was to assess whether: 
1. Gamma-delta T cell frequency was correlated with CD4 count, used as a marker of HIV disease 
progression. 
 2. The frequency of the VD2 TCR subset of gamma-delta T cells differed in healthy controls 
compared with HIV or HIV/TB co-infected patients.  
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2. MATERIALS AND METHODS 
 
2.1. Study samples 
 
Ethics approval was obtained from the University of Witwatersrand human ethics committee and 
the following ethics number received: M10228. 
The study was a prospective study which was performed over a period of 2 months. A total number 
of 49 samples were collected. Samples from patients were collected at the Charlotte Maxeke 
Johannesburg Academic Hospital from 1 July 2011 until 31 August 2011. Samples were analyzed 
at the National Health Laboratory Services, department of Molecular Medicine and Haematology 
based at the Charlotte Maxeke Johannesburg Academic Hospital. 
Seventeen control samples were collected in ethylene-diamine-tetra-acetic acid (EDTA) anti-
coagulated tubes from health care workers at the Charlotte Maxeke Johannesburg Academic 
Hospital. Participants signed informed consent for blood to be used for the study. Controls were 
given the option of free HIV testing with appropriate counseling by independent counselors not 
involved with the study. Those that consented were taken to an HIV testing centre where a rapid 
HIV test was performed. Seventeen control patients were enrolled of which four (A6, A8, A12, 
A13) refused consent for the HIV testing but were included in the study. One control patient tested 
HIV positive. This patient was subsequently referred to the HIV clinic and was excluded from the 
study analysis. During processing of samples, further exclusion of samples was required. This 
resulted in samples A1, A2, A3 and A4 being excluded. These samples were excluded because the 
antibody we used to mark gamma-delta T cells for this batch was found to stain sub-optimally. 
Samples A14, A15 were also excluded from our analysis because there were too few events noted 
on these sample plots. Therefore, 10 control samples in total were analyzed in total. 
Patient samples were collected included two groups. The first group included patients that were 
HIV positive and had no symptoms or signs of current Tuberculosis. TB microscopy was not 
collected routinely on this patient group and exclusion of Tuberculosis was based on absence of 
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symptoms and signs of Tuberculosis. Symptoms for which patients were screened included 
productive cough, night sweats and loss of weight. Signs included pleural effusions and signs of 
immunosuppression such as cachexia. Data was collected on a patient data sheet (Appendix 4). 
These samples were obtained from the Charlotte Maxeke Johannesburg Academic hospital HIV 
outpatient clinic. A total number of seventeen patients were collected in this group. During sample 
processing, it was found that B5 had too few cells for analysis and was thus excluded from the 
analysis. A total of 16 samples in this group were thus used in the final analysis. 
The second group included patients that were HIV positive with recent onset (previous two weeks) 
of smear positive Tuberculosis and that had only been on anti-Tuberculosis treatment for less than 
4 days or had not started anti Tuberculosis treatment. These samples were obtained from the 
medical and infectious disease wards at the Charlotte Maxeke Johannesburg Academic Hospital. 
The sputum results for smear positivity of each patient were obtained from the microbiology 
laboratory. All patients who had been on anti-Tuberculosis therapy for longer than 4 days and who 
did not have smear-positive sputum result were excluded. There were no pregnant women in the 
cohort. The age range for all patients and health care workers was between 20-60 years old. A total 
number of fifteen patients in this group were collected. There were no exclusions in this group. 
Therefore, all the samples in this group were used in the analysis. 
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Table 3: Enrollment and exclusion numbers 
 
 GROUP A 
(CONTROLS) 
GROUP B(HIV+TB-) GROUP C 
(HIV+TB+) 
TOTAL NUMBER 
SAMPLES COLLECTED 
17 samples 17 15 
EXCLUSIONS A1, A2, A3, A4 excluded 
due to poor staining 
A7 excluded due to HIV 
positivity 
A14, A15 excluded due to 
too few cells for analysis 
 
B5 excluded due to too few 
cells for analysis 
No exclusions in this group 
FINAL SAMPLES 
ANALYSED 
10 samples 16 samples 15 samples 
 
2.2. CD4 testing 
Blood for CD4 testing was taken from the patient and sent to the National Health Laboratory 
Service (NHLS) laboratory for testing according to their standard procedure. The CD4 testing was 
part of routine investigations performed on the patient. 
2.3. Peripheral blood mononuclear cell (PBMC) isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation over Ficoll 
Hypaque gradients. The PBMC’s were spun at a speed of 3000 rcf (relative centrifugal force) and 
washed three times in phosphate buffered saline (PBS). An antibody cocktail was prepared which 
consisted of each appropriate volume of the nine antibodies multiplied by the number of samples 
for testing. The staining volume of each antibody was obtained by titration (see below). Each 
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sample was then stained using the antibody cocktail for each day, to minimize pipetting 
inaccuracies.  
2.4. Flow cytometric acquisition and analysis 
All the data was recorded on the LSRII flow cytometer (BD Biosciences) using FACSDIVA 
software (BD Biosciences) for acquisition. FlowJo software (Treestar, USA) was used for analysis. 
Approximately 200 000 events were recorded for each sample.  
2.4.1. Quality control: 
Daily quality control of the instrument was performed as per routine laboratory procedure by use 
of 1 X beads (midlevel fluorescence beads) (BD Biosciences). Any shift of fluorescence compared 
to the beads previous position is recorded and only minor shifts which remain within set gates are 
considered acceptable. 
2.4.2. Compensation 
BD Comp Beads are polystyrene particles that have been coupled to an antibody specific for the 
IGH Kappa light chain of a mouse. Each set contains a negative control which has no binding 
capacity. When these are mixed with a mouse antibody conjugated to a fluorochrome, BD Comp 
Beads are able to provide distinct positive and negative stained populations. BD Comp Beads were 
thus used in the experiment to set compensation levels and to standardize experiments. 
For compensation, nine tubes were prepared which each contained one antibody in the previously 
titrated volume. A positive and negative compensation bead was included in each tube (IgG 
capture beads, BD Biosciences). These tubes were then run on the LSR and photomultiplier tube 
voltages (PMTs) were adjusted according to expected brightness of the specific fluorochrome 
using histogram (H) gates. For each flourochrome, a gate was applied around the population where 
the fluorochrome was originally expressed on the first run. H-gates were applied to each individual 
fluorochrome for each sample tested and PMT’s adjusted to bring the population within the gate.  
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2.4.3. Titration of antibodies 
When preparing a sample for flow cytometric analysis, titration of antibodies is essential to find 
the optimal concentration of antibody that approaches the saturation level of binding sites. This 
will ensure that a fluorescent signal emission is proportional to the antigen in the sample. CD4 
Alexa700 and CD8 PerCP CY5.5 had been titrated for the initial antibody panel. As illustrated in 
Appendix 9, the titration of CD8 Beta was performed. A series of dilutions of the antibody was 
prepared as follows: 
 
Table 4: Titration of CD8 Beta 
 
 
TUBE 1 2 3 4 5 6 7 8 
VOLUME OF 
CD8 
BETA(µL) 
0.625 1.25 2.5 5 7.5 10 20 UNSTAINED 
TUBE 
TOTAL 
STAINING 
VOLUME(µL) 
50 50 50 50 50 50 50 50 
 
The mean fluorescence intensity for the antibody was plotted against the antibody staining volume. 
The optimal mean fluorescence intensity for the antibody was chosen according to the point of 
saturation for the specific antibody.  
Due to fluorescence spillover of antibodies, the initial antibody panel was altered which required 
further titration of another set of antibodies. These antibodies were serially titrated. The mean and 
median fluorescence intensity was determined and the final optimal volume for each antibody was 
chosen .The final volume chosen for CD4 +Alexa700 was 2,5ul and for CD8+ Alpha was 5ul. The 
other antibodies had been previously titrated by our laboratory. 
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2.4.4. Fluorescence-minus-one (FMO) experiments 
Fluorescence-minus-one (FMO) experiments involve omitting one fluorochrome at a time from 
each tube and looking for spillover fluorescence from the remaining fluorochromes into the 
channel of the omitted colour. FMO’s were prepared for each antibody. Results of the FMO 
experiment required redesign of the panel as shown below. 
 
Table 5: Initial and new antibody panel  
 
ANTIBODY INITIAL 
FLUOROCHROME 
FINAL 
FLUOROCHROME 
CLONE 
NUMBER 
MANUFACTURER 
CD4 PercP Alexa 700 RPA-T4 Bio Legend, SanDiego, 
California 
CD3 AmCyan AmCyan SK7 BD Biosciences, SanJose, 
California 
CD8 Alpha Alexa700 PerCP-CY5.5 RPZ-T8 Bio Legend, SanDiego, 
California 
CD8 Beta APC APC R22-33 BD Biosciences, SanJose, 
California 
CD16/CD56  Pacific blue  Pacific blue CD16:3G8 
CD56:B159 
BD Biosciences, SanJose, 
California 
VD2 TCR FITC   FITC δG9 BD Biosciences, SanJose, 
California 
CD19 PE-Cy7 PE-Cy7 REF:IM3628 Beckman Coulter, Brea, 
California 
GAMMA 
DELTA TCR 
PE-Cy5/PerCP PE-Cy5/PerCP REF:IM2662 Beckman Coulter, Brea, 
California 
INKT 6B 11 PE PE 6B11 Bio Legend, SanDiego, 
California 
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The initial FMO experiments indicated spillover. Spillover is the phenomenon that occurs when 
fluorescence emission of one fluorochrome is detected in a second detector designed to measure 
signals from a second fluorochrome. In the CD3 FMO experiments, omission of CD3 AmCyan 
while running a panel comprising the other eight fluorochromes showed spillover into the AmCyan 
channel (figure 1). Omission of CD4 PerCP-CY5.5 while running a panel comprising the other 
eight fluorochromes also showed spillover into the  PerCP-CY5.5 channel (figure 2). Spillover 
into the CD8 Beta APC channel also occurred (figure 3). 
These spillover effects necessitated a substitution in the panel. We used CD4 Alexa 700 and CD8 
Alpha PerCP-Cy5.5 instead for the new antibody panel and reanalyzed FMOs. No spillover effects 
occurred with our new panel. 
 
 
 
Figure 1: Spillover into the AmCyan channel. The above plot was from a 
sample in which the fluorochrome AmCyan was omitted. There should be no 
events in the AmCyan channel. This plot shows events on the x axis (AmCyan) 
which indicates that another fluorochrome is spilling over into the AmCyan 
channel. 
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Figure 2: Spillover into PerCP-CY5.5. The above plot was obtained in an 
experiment which omitted PerCP-Cy5.5 from the tube. All other 
fluorochromes were present in the tube. In view of the omission of PerCP-
Cy5.5 from the tube, no events are expected to occur in the PerCP-Cy5.5 
channel. However, events in this channel are noted (see boxed events), 
indicating spillover of another fluorochrome into the PerCP-Cy5.5 channel 
 
 
 
Figure 3: Spillover of other fluorochromes into CD8 Beta APC. This plot 
similarly shows events in the APC channel when APC is omitted which 
indicates spillover of another fluorochrome into APC channel. 
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2.5. Manual adjustment of compensation matrix 
Digital compensation was originally performed using FlowJo software. Digital compensation did 
not fully compensate each fluorochrome against each other as is common in multicolour 
panels.Therefore, manual compensation was performed by iteratively plotting each fluorochrome 
against every other fluorochrome and adjusting the compensation matrix until the single–stained 
and unstained compensation beads showed equal fluorescence in all channels other than the stained 
fluorochrome channel. 
2.6. Exclusions 
Although manual compensation was performed for each sample,it was not possible to fully  
eliminate compensation issues from all the samples.Samples A1,A2,A3 and A4 belonged to the 
same batch of samples which were collected and analysed on the same day.These samples were 
excluded because the  antibody the used to mark gamma-delta T cells for this batch was found to 
stain suboptimally.Sample numbers A14, A15 and B5 were excluded from our data because their 
were too few events noted in these plots. 
2.7. Gating strategy 
Lymphocytes were selected on the basis of forward scatter and low side scatter followed by the 
selection of T cells on the basis of CD3 positivity, which is lineage specific for T cells. B cells 
were identified using CD19. From the total CD3 population, the other T cell subsets were selected. 
These included CD4, CD8 Alpha, CD8 Beta, NK- T cells and gamma-delta T cells. There were 
two gamma- delta T cell subsets included in the study: gamma-delta TCR and VDelta2TCR (VD2 
TCR). 
As depicted in figure 5, gamma delta TCR was plotted on the y-axis and VD2 TCR was plotted on 
the x–axis. The frequency of total gamma-delta T cells was calculated by adding the top two 
quadrants of each plot. The VD2 TCR subset was evaluated by adding the top and bottom right 
hand quadrants of each plot. 
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2.8. Statistical analysis 
Descriptive statistics using medians, minimum and maximum values were used to characterize 
age, gender CD4 count and number of patient on HAART. Age differences between groups was 
analyzed using a Chi Square test. CD4 count between group B and C was analyzed using a Mann 
Whitney test. The proportion of patients on HAART were compared between groups B and C 
using a two tailed Fishers Exact test. These tests were performed using Graph-Pad Prism software, 
version 6 (La Jolla, California). 
Gamma delta T cells, VD2 T cells, CD4 and CD8 frequencies in HIV, HIV+ TB+ and control 
groups were compared using non-parametric one way analysis of variation (ANOVA) testing with 
Kruskal-Wallis. Graph Pad Prism software was used. Post-hoc comparisons were done using 
Dunns analysis. The levels of significance was chosen as p<0.05. Correlations were performed 
using the Spearman non-parametric method. 
 
3. RESULTS: 
The study population included black South African patients from the HIV clinic and respiratory 
wards at the Charlotte Maxeke Johannesburg Academic Hospital. Appendix 8 shows the patient 
demographic profiles. A comparison with respect to age, gender, HAART therapy and CD4 counts 
was done using a uni-variate analysis on Graph-Pad Prism software version 6 (La Jolla, 
California). 
 
Gender differences were evaluated in the cohort. There was a total number of 18 males and 31 
females in the cohort. There were 4 males and 13 females in group A. There were 8 males and 9 
females in group B. There were 6 males and 9 females in group C. Differences in gender was 
analyzed using a Chi Square test. No difference with respect to gender was found between the 
groups (p=0.3458) (table 6). 
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Table 6: Gender differences in the cohort 
 
 
 GROUP 
A 
GROUP 
B 
GROUP 
C 
TOTAL 
NUMBER 
MALES 4 (23% 
of group 
A) 
4 (30% 
of group 
B) 
6 (40% 
of group 
C) 
18 (36% of 
total) 
FEMALES 13 9 9 31 
TOTAL  17 13 15 49 
 
 
All three groups were assessed for age differences. The median age in group A was 40 years, in 
group B was 38 years and in group C was 34 years. The youngest person was 20 years old in group 
A and group C. The oldest person was 84 years old in group A. Age differences were analyzed 
using a Chi-square test. There was no difference found between the groups with respect to age 
(p=0.2916) (table 7). 
 
 
Table 7: Age differences in the cohort 
 
 
AGE IN 
YEARS 
GROUP 
A 
GROUP 
B 
GROUP C 
MINIMUM 
AGE 
20 31 20 
MEDIAN 
AGE  
40 38 34 
MAXIMUM 
AGE  
84 71 52 
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The minimum CD4 count was 10 x 10^6/l in group C and the maximum CD4 count was 739 x 
10^6/l in group B. Using a Mann Whitney test, the median CD4 count (median=90 µl) was 
statistically lower than the median CD4 count in group B (median=465 µl) (p=0.002) (table 8).  
 
 
Table 8: CD4 counts in the cohort 
 
 
 GROUP B  GROUP C 
MINIMUM (µl) 45 10 
MEDIAN (µl) 465 90 
MAXIMUM 
(µl) 
739 477 
 
 
In group B, 15 patients were on HAART and 2 patients were not on HAART. In group C, 7 patients 
were on HAART and 8 patients were not on HAART. Using a 2 tailed Fishers exact test, there was 
a significant difference in the proportion of patients receiving HAART therapy and those not on 
HAART therapy (p=0.021). Table 9 shows the number of patients on HAART therapy for each 
group. 
 
 
 
 
 
 
 
 
 
 
26 
 
Table 9: Number of patients on HAART therapy  
 
 
 HAART THERAPY 
GROUP B 15 patients on HAART, 2 patients not on 
HAART 
GROUP C 7 patients on HAART, 8 patients not on 
HAART 
 
 
 
3.1. Frequencies of Gamma-delta T cell subsets differ between HIV infected patients 
and healthy controls 
It was hypothesized that there may be differences in the frequency of gamma-delta T cells in HIV 
infected patients compared to healthy controls. The total gamma-delta T cells as well as the VD2 
subset (CD3+, Gamma-delta TCR+,VD2 TCR+) and the non-VD2 subset (CD3+, Gamma-delta 
TCR+, VD2 TCR-) was analyzed. 
The frequency of total gamma-delta T cells as a percentage of T cells was higher in HIV infected 
patients compared to healthy controls (p=0.0052, median 11.4% vs.2.53%). HIV infected patients 
also had higher values compared to HIV+TB+ patients (median 4.92%) although this was not 
statistically significant. 
Similarly, the non-VD2subset, as a frequency of total T cells, was also higher in HIV infected 
patients compared to healthy controls (p=0.0005, median 11.4% vs.2.3%)  
These results differed to those noted for the VD2 subset of gamma-delta T cells. The frequency of 
the VD2 subset as a percentage of total CD3 T cells was higher in healthy controls compared to 
HIV+TB+ patients (p=0.0318 , median 5.88% vs.0.87%). The VD2 subset was also higher in the 
healthy controls than the HIV+ group (median 0.87%) although this did not reach statistical 
significance. 
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There was no difference between controls and HIV+ and HIV+TB+ groups in the frequency of 
gamma-delta T cells expressing the cytotoxic T cell marker CD8 Alpha (p=0.1252). 
There was no significant correlation between the CD4 count and the frequency of gamma-delta T 
cells, or the VD2 subset, as a percentage of CD3 T cells, in HIV infected or HIV+TB+ patients 
(data not shown). 
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Figure 4: 
 
A:  The frequency of total gamma-delta 
T cells, as a percentage of the CD3 
population, was higher in HIV infected 
patients than healthy controls (p=0.0052).  
 
B: The non VD2 subset also had a higher 
frequency in HIV infected patients than 
controls (p=0.0005).  
 
C: In contrast, the VD2 subset had a 
lower frequency in HIV+TB+ patients 
compared to healthy controls (p=0.0318). 
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Figure 5: Flow cytometric plots of gamma-delta T cells. The first lymphocytes were gated 
according to forward and side scatter. Then CD3 positive cells were gated. Then the gamma 
delta TCR was plotted on the y-axis and VD2 TCR is plotted on the x–axis. The frequency of 
total gamma-delta T cells was calculated by adding the top two quadrants. The VD2 TCR 
subset was evaluated by adding the top and bottom right hand quadrants. 
A17=healthy control patient. B7=HIV+ patient. C9=HIV+TB+ patient. The VD2 subset 
appears absent in this HIV+TB+ patient. 
 C9 
A17 B7 
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3.2. Cytotoxic T cells and CD4 T helper cells 
The frequency of cytotoxic T cells (CD3+, CD8 Alpha+) as a percentage of CD3+ T cells was 
significantly increased in HIV+TB+ patients compared to healthy controls (p=0.0009, median 
=73.4% compared to 40%) (Figure 6). The HIV+ group (median 59.3%) also had higher cytotoxic 
T cell frequency than the control group (median 40%), not reaching statistical significance. This 
is likely due to the lower CD4 frequency, as a percentage of CD3+ T lymphocytes, known to occur 
in HIV. 
T  helper cell (CD3+CD4+)  frequency was lower in HIV infected and HIV+TB+  patients 
compared to healthy controls (p=0.0409, medians=35% for HIV+ patients, 30% for HIV+TB+ 
patients and 53,8% for healthy controls).  
 The absolute CD4 count was negatively correlated with the CD8+T cell frequency for both HIV 
infected (p=0.009 and Spearman rho=-0.062) and HIV+TB+ patients (p<0.001 and Spearman 
rho=-0.814) (figure 8). 
 
 
 
 
 
 
 
Figure 6: Cytotoxic T cells (CD3+, CD8 Alpha+), as a percentage of CD3+ T cells,  had  a 
higher frequency  in HIV+TB+ patients compared to controls (p=0.0009). Helper T cells 
(CD3+, CD4+), as a percentage of CD3+ T cells, were lower in HIV+TB+ patients compared 
to healthy controls (p=0.0409). 
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Figure 7: Flow cytometric plots of helper (CD3+CD4+) and cytotoxic (CD3+ CD8+) T 
cells. CD4 is plotted on the X axis and the CD8 Alpha is plotted on the Y axis of the 
largest plots. Total cytotoxic T cell frequency was calculated by adding the top right 
and left quadrants. Total CD4 T cell frequency was calculated by adding the top 
and bottom right quadrants. 
A17=healthy control, B6=HIV+ patient, C5=HIV+TB+ patient. 
Cytotoxic T cells (CD3+ CD8+) as a percentage of CD3 are increased in HIV+ and 
HIV+TB+ patients compared to healthy controls. T helper cells (CD3+, CD4+) are 
markedly reduced in HIV+ and HIV+TB+ patients compared to healthy controls. 
C5 
B6 A17 
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Figure 8: These graphs show inverse correlations between CD4 count on the X axis and CD8  
Alpha, as a percentage of CD3 T cells, on the Y axis, for group B (rho=-0.063, p=0.009) and group 
C (rho=-0.814, p<0.001). 
 
4. DISCUSSION 
Gamma-delta T cells are a unique population of immune cells which have been a subject of recent 
interest due to their distinct property of combining conventional adaptive functions with rapid 
innate immune responses (70). Their diverse scope of antigen recognition has placed them at the 
forefront of research into prevalent viral and bacterial infections worldwide (70). In addition, 
gamma-delta T cells have the potential to become reagents in immunotherapies and vaccines for 
cancers, autoimmune disease and infections such as HIV and Tuberculosis (88-91). There is, 
however, a paucity of data on gamma-delta T cell frequency in HIV infections and human 
Tuberculosis in Africa, and no data from the South African population. 
Gamma-delta T cells in HIV infected Tuberculosis patients was enumerated. A multi-colour flow 
cytometric panel which allows the inclusion of many markers simultaneously was used. This 
enabled multiplexing the markers CD3, gamma-delta TCR (expressed by all gamma-delta T cells) 
and VD2 TCR (a subset of gamma-delta T cells expressing the VD2 variable gene in their T cell 
receptor). Markers of conventional T helper cells (CD4), cytotoxic T cells (CD8 Alpha) and B 
cells (CD19) were included. Additionally markers of other innate-like lymphocytes (NKT cells) 
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were included (CD16, CD56, CD8Beta and CD6B11). Analysis of the NKT cell subset will not 
form part of this dissertation.  
A healthy control group and an HIV infected patient group with and without active Tuberculosis 
was enrolled. The Tuberculosis group comprised HIV positive patients that were smear positive 
for acid fast bacilli in sputum. The HIV group was screened for Tuberculosis symptoms by a 
questionnaire and directed investigations if necessary. The control group comprised health care 
workers from the Charlotte Maxeke Johannesburg Hospital. Testing for latent Tuberculosis was 
not performed due to ethical, logistical and financial constraints in offering isoniazid treatment to 
participants found to be harboring latent Tuberculosis. Most health care workers and HIV infected 
patients in our setting are expected to have been previously exposed to Tuberculosis (92, 93). 
There was no statistical difference in age or gender between groups in our cohort.  
The frequency of total gamma-delta T cells, expressed as a percentage of total T cells, were 
significantly increased in HIV infected patients compared to health care workers. There was a 
trend to higher gamma-delta T cells in the HIV+ TB+ group compared to healthy controls; however 
this did not reach statistical significance. 
Increased gamma-delta T cells in HIV and dual HIV+ TB+ patients may not reflect an increase in 
absolute numbers, rather an increase in proportion of CD3+ T cells as a result of the known loss 
of CD4+ T cells that occurs with HIV infection.   
When divided into VD2 and non-VD2 subsets of gamma-delta T cells, the non-VD2 subset showed 
a similar pattern of increased frequency in HIV patients, and a trend to higher frequencies in HIV+ 
TB+ patients, in comparison with healthy controls. 
Paradoxically, however, the VD2 T cell subset was significantly reduced in the HIV+ TB+ group 
compared with healthy controls, and showed a non-significant trend to lower levels in the HIV 
group. The reduced VD2 cells in HIV and in HIV+ TB+ patients, as a frequency of CD3+ T cells, 
mirrors the loss of CD4+ T cells in these patients and likely reflects a loss in absolute numbers of 
these cells. 
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There is thus a skewing in the gamma-delta T cell repertoire in HIV infected patients with a 
decrease in the VD2 subset in proportion to the non-VD2 subset. This decrease in the VD2 subset 
was particularly marked in HIV infected patients with active Tuberculosis. The non-VD2 subset 
appears elevated in frequency but this may be a reflection of lower CD4+ and VD2 T cells in the 
total CD3+ population. 
Gamma-delta T cells are of interest in Tuberculosis as they react to phospho-antigens found in the 
lipid wall of the mycobacterium (44-47). Gamma-delta T cells are non-MHC restricted, unlike the 
more common alpha-beta T cells. They express the T cell receptor in a limited repertoire (45, 46, 
94, 95). 
Recent evidence suggests that gamma-delta T cells are essential immune regulators of several 
viruses. Vaccinia virus infected mice have increased numbers of IFN-gamma secreting splenic 
gamma-delta T cells after 2 days of infection corresponding with an innate immune response (96). 
Mice infected with West Nile Virus show reduced numbers of gamma-delta T cells to primary and 
secondary infection and it is suggested that gamma-delta T cells form memory T cells in this setting 
(97). Gamma-delta T cells are also expanded in CMV infections in humans (98, 99). 
Regarding the patient groups in our cohort, there was a statistically significant difference noted in 
the proportion of patients receiving HAART therapy. More HIV+TB+ patients (group C) were not 
on HAART therapy compared to group B patients. Several studies have found that HAART 
therapy increases the VD2 T cell subset in HIV+ patients (95, 100).It is difficult to assess whether 
the differences in the VD2 T cell subset noted in our group is associated with active Tuberculosis 
or with longer HAART duration and higher CD4 counts.  
The high proportion of patients with previous TB in group B (16 patients of 17 with known 
previous TB) illustrates high burden of disease in our setting and highlights the logistical difficulty 
in obtaining cohorts with only HIV infection and no history of Tuberculosis disease. It was 
logistically difficult to find a Tuberculosis only (HIV negative) group at our tertiary care centre. 
Thus, the relative contribution of HIV disease and TB disease to the skewed gamma-delta T cell 
repertoire is difficult to determine and would require further studies. Decreased frequency of VD2 
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T cells compared with healthy controls may be associated either with HIV or previous TB infection 
in group B 
The loss of VD2 TCR that occurs with HIV infection is now well established (91). The findings 
of a reduction in the VD2 TCR subset  in HIV+ patients with active Tuberculosis is supported by 
a similar study which recruited HIV infected patients with opportunistic infections including 
Tuberculosis, candidiasis, hepatitis C, herpes zoster and salmonella (81).The VD2 subset was 
reduced in HIV+ patients with opportunistic infections compared to asymptomatic HIV infected 
patients. In addition, this study performed stimulation testing and found a reduction in the 
production of IFN-gamma from VD2 TCR T cells in HIV+ patients. This data suggests that a 
decreased frequency and function of VD2 T cells may be associated with the presence of 
opportunistic infections (81).  
Most of the patients in our cohort had lower than detectable viral loads. The VD2 TCR subset of 
gamma delta T cells correlated directly with CD4 T cell count and inversely with viral loads in a 
Chinese cohort (101).The VD2 TCR response is preferentially depleted during HIV infection 
(102).The depletion of the VD2 TCR subset occurs early during  the disease with an ongoing 
depletion noted during progression of HIV (103). Potential immunotherapeutic strategies for 
increasing the VD2 TCR response in HIV disease are being explored (104). 
With regards to CD4+ T cell and CD8+ T cell frequencies, it was found that healthy controls had 
the highest frequency of CD4+ T cells and the HIV+TB+ co-infected group had the lowest 
frequency. HIV+TB+ patients had more CD8+ T cells as a percentage of CD3+ T cells compared 
to HIV+ patients (not significant) and to healthy controls (significant). The high CD8 frequency, 
when expressed as a percentage of CD3+ T cells, is likely due to the HIV-associated loss in 
absolute numbers of CD4 T cells. Supporting this interpretation, the CD4 frequency of both HIV+ 
and HIV+TB+ patients was inversely proportional to CD8+ T cells. These findings are in keeping 
with the known decline in CD4+ T cells during HIV progression. Multiple mechanisms for CD4 
T cell decline have been described. These include cytopathic effect of the virus and death of 
uninfected cells (24, 105). 
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Similarly, the immune responses of peptide-specific CD4+ and CD8+ T cells and non-peptide 
specific Vgamma2Vdelta2 T cells during clinical quiescence of latent mycobacterium tuberculosis 
infection in HIV infected humans has been analysed (106). The study was performed in China 
using 4 groups of patients as follows: HIV+ with active Tuberculosis, HIV+ with latent 
Tuberculosis, HIV+ patients with no Tuberculosis and a healthy control group with no HIV 
infection. Active Tuberculosis patients were identified by clinical symptoms, abnormal chest X-
rays, tuberculosis culture positive and smear-positive acid fast bacilli in sputum cultures. The 
patients with latent Tuberculosis were identified using a T-SPOTTB assay. Absolute cell numbers 
were calculated based on flow cytometric data and complete blood counts. The study found that 
the frequency and absolute numbers of CD4+ T cells in all 3 HIV infected groups were 
significantly lower than the healthy controls, as expected. The HIV+ patients with active 
Tuberculosis had lower CD4+T cell counts than the HIV+ patients with latent Tuberculosis. Mean 
absolute numbers of CD8+ T cells in the HIV+ patients with latent Tuberculosis were significantly 
higher than those in the HIV+ patients with active Tuberculosis. Both percentage and absolute 
numbers of gamma-delta T cells and VD2 T cells in the HIV+ patients with active Tuberculosis 
were also significantly lower than those in HIV+ patients with latent Tuberculosis (106). 
We did not include analysis of cell function in our study. However, in studies of antigen specific 
T cell responses was found that potent immune responses of HMBPP-specific gamma-delta T cells 
and VD2 T cells occurred. PPD-specific CD8+ T cells were associated with the latent stage of 
Tuberculosis. It was concluded that gamma-delta and CD8+T cells are anti-Tuberculosis effector 
T cells in HIV infected patients with low CD4 T cell counts (106). Another study found that the 
IFN-gamma VD2 T cells in HIV+ Latent Tuberculosis patients were much greater than those in 
the HIV+ active Tuberculosis group (106).  
HIV+ patients with no concomitant Tuberculosis have been studied using flow cytometry to 
analyze the function of VD2 T cells. Samples were stimulated with mycobacterium tuberculosis. 
VD2 T cells were found to be reduced after stimulation (106). It has been suggested that the 
continuous antigenic stimulation that occurs with HIV infection may be the reason for the 
reduction of VD2 T cell frequency in HIV progression (94). 
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Another activation study showed similar results. PBMC’s were stimulated for 7 days with 
microbial antigens which included candida albicans, salmonella typhimurium as well as 
mycobacterium tuberculosis. The VD1 and VD2 T cells were quantified as a percentage of CD3+ 
T cells. The VD2 T cells were increased in response to stimulation with microbial antigens ex vivo 
(107). 
Bordon et al  used spectratyping to determine the size distribution of VD2 T cell transcripts in 
peripheral blood mononuclear cells in HIV positive subjects and showed that the decreased VD2 
T cell frequency in HIV+ patients seems to recover with the initiation and duration of HAART 
(100). Other studies have supported this concept showing that interruption of HAART, leads to a 
reduction in total gamma-delta T cells (95). Poccia et al showed that HIV positive patients with 
opportunistic infections including candidiasis, Tuberculosis, herpes zoster and salmonella had 
markedly increased gamma-delta T cell subsets as a percentage of CD3 after only 3 months of 
HAART (95). 
Other studies have shown a reduction of gamma-delta T cells in the peripheral blood of patients 
with active Tuberculosis and have hypothesized that this may be a reflection of a migration of 
these gamma-delta T cells to the site of infection in the lung epithelia (44, 49, 108). Increased 
numbers of gamma-delta intraepithelial lymphocytes (IEL) were noted in most HIV infected 
patients suggesting that they may contribute to the first line of defense against infectious organisms 
at the site of infection (109). Pleural effusion fluid contained gamma-delta T cells (49). Gamma-
delta T cell subsets taken from broncho-alveolar lavages from active Tuberculosis patients 
displayed a functional anergy (not able to produce cytokines) compared to peripheral gamma delta 
T cells (76). 
A major strength of this study was that it is one of the first studies to analyze gamma-delta T cells 
in black South African patients. A prospective study design which allowed us to screen and enroll 
candidates for the study using appropriate exclusion and inclusion criteria was chosen. All patients 
and controls were screened and enrolled and samples were sent for CD4 counting on the same day 
as enrollment. Flow cytometry was performed on fresh blood rather than cryo-preserved material 
and therefore is more likely representative of in vivo cell frequencies. All samples were processed 
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within 4 hours of blood drawn. The controls consisted of a healthy health care worker group as 
well as an HIV infected control group. 
Multi-colour flow cytometry also has the advantage of being able to analyze a lot of information 
about different cell types in the body in a single sample using a small amount of blood. A stringent 
daily quality control of the flow cytometer was ensured by daily running of 1 x beads (87). 
Limitations of this study included the absence of a Tuberculosis positive but HIV negative control 
group which was difficult to obtain in our setting where HIV infection is prevalent. Not all of the 
healthy controls gave consent for HIV testing and counseling. Only thirteen out of the seventeen 
healthy controls agreed to HIV testing. One out of these thirteen that consented was found to be 
HIV positive and was consequently excluded from the study. The others were all found to be HIV 
negative.  
Gamma-delta T cell frequency alone was analyzed. The functional properties such as cell 
proliferation and cytokine production were not analyzed. This would have entailed additional 
stimulation time per sample and further funding which was not available. 
A disadvantage of multi-colour flow cytometry is the complex compensation issues that can occur 
when using multiple fluorochromes. The compensation difficulties experienced was complex and 
required panel adjustments following the FMO experiments. Even with the new panel, the 
compensation was not perfect in the groups after manual adjustment of the compensation matrix. 
The compensation issues in the HIV+TB+ group were particularly evident. This may have also 
been due to increased incidence of non-specific binding of monoclonal antibodies (personal 
communication Prof Debbie Glencross) which occurs in dual infected HIV+ TB+ patients. The 
best compensation set attempted was used. During the flow cytometric analysis, height and width 
for forward and side scatter was not acquired. This would have been beneficial to exclude debris 
to allow easier manual compensation. The cells were spun at 3000 RCF which is routine in the 
laboratory. This speed may have been too high for HIV and TB co-infected samples and 
contributory to suboptimal cell yields. Centrifugation speeds were not optimized specifically for 
HIV/TB co-infected samples.  
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5. CONCLUSION: 
Gamma-delta T cells in HIV infected Tuberculosis patients were enumerated. The VD2 subset 
expressed as a frequency of total T cells was significantly reduced in the HIV+ TB+ group 
compared with healthy controls, and showed a non-significant trend to lower levels in the HIV 
group. Therefore, a skewing of the gamma-delta T cell repertoire in the dual HIV and TB infected 
patients with a decrease in the VD2 subset occurred. This mechanism of alteration in gamma-delta 
T cell frequency, in particular the loss of VD2 T cells, deserves attention in elucidating 
susceptibility to Tuberculosis disease in HIV infected patients. 
The frequency of total gamma-delta T cells, expressed as a percentage of total T cells, was 
significantly increased in HIV infected patients compared to health care workers. This may, 
however, be a reflection of lower CD4 T cells and VD2 gamma delta T cells in the total CD3 
positive population. 
 
6. RECOMMENDATIONS: 
Further studies which would be of value are the assessment of the VD2 T cell subset of gamma-
delta T cells in the pleural fluid of active Tuberculosis patients for comparison with peripheral 
blood frequencies in a South African setting. This would enable a better understanding of the 
function of these cells at the site of infection. Studies including activation markers for gamma-
delta T cells such as IFN-gamma and interleukins should also be included in future studies for 
assessment of gamma-delta T cell function. 
Due to the complex nature of multicolour flow cytometric compensation and poor sample quality 
of HIV positive samples, including paucity of lymphocytes and non-specific binding of 
monoclonal antibodies which occurs with HIV infection, it is recommended that confirmatory 
studies using 5-7colour flow cytometric panels with carefully selected markers and fluorophores 
performed to potentially avoid compensation issues. 
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